• ̍̍ CSE: BRAX
  • ̍̍ OTC: BRAXF
  • ̍̍ FWB: 4960

BRAXIA SCIENTIFIC

May 20, 2022

Braxia Scientific Receives Health Canada Special Access Program Approval to Provide Psilocybin-Assisted Therapy for Depression in Ontario

Health Canada approval is for a patient with the indication of Major Depressive Disorder, in the absence of terminal medical illness or end of life distress. Approval marks Braxia’s first Special Access Program (SAP) approval for use of psilocybin in Ontario. To date Braxia’s experienced therapists have delivered psilocybin-assisted therapy treatments to 16 individuals with depression through its proprietary clinical trial commenced late 2021.   TORONTO, May 20, 2022 / Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing and advancing innovative ketamine and other innovative treatments for people living with depression and related mental health disorders. Braxia Scientific is pleased to announce that Health Canada has approved the Company’s application to the Special Access Program (“SAP”) to provide psilocybin-assisted psychotherapy for a patient with Major Depressive Disorder in...

May 19, 2022

Braxia Scientific to Present at H.C. Wainwright Global Investment Conference, Miami from May 24-26, 2022

TORONTO, ONTARIO May 19, 2022 - Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the H.C. Wainwright Global Investment Conference from May 24 – 26, 2022 in Miami, Florida. Braxia Scientific CEO Dr. Roger McIntyre will present an overview of the Company's business, including its progress on increasing access to novel ketamine and psychedelic treatments for patients with depression and expanding the clinical research infrastructure required to execute on the Company's growing pipeline of registered clinical trials alongside third-party sponsors. Braxia's trials include Canada's first multi-dose psilocybin-assisted therapy trial which commenced in November 2021 and is expected to report preliminary results in the coming weeks. Dr. McIntyre will also be available to host one-on-one meetings with institutional investors registered with H.C. Wainwright...

June 8, 2021

KETAMINE AND ESKETAMINE TREATMENT GUIDANCE

AMERICAN JOURNAL OF PSYCHIATRY PUBLISHES INTERNATIONAL KETAMINE AND ESKETAMINE TREATMENT GUIDANCE LED BY BRAXIA SCIENTIFIC CEO DR. ROGER MCINTYRE International Expert Opinion and Implementation Guidance outlines Ketamine and Esketamine treatment parameters setting the standard for the clinical implementation of these rapid-acting treatments in treatment resistant depression  Guidance published in the official Journal of the American Psychiatric Association establishes Braxia Scientific as an international leader in the rapidly evolving industry of Ketamine, Esketamine and rapid acting antidepressants  TORONTO, ONTARIO June 9, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics  providing novel ketamine treatments for persons with depression and related disorders, is pleased to announce the American Journal of Psychiatry, the most widely read psychiatric journal in the world, has published the International Expert Opinion and Implementation Guidance (the “Guidelines”) for the clinical use of...